| Abstract |
Abstract：ObjectiveTo investigate the clinical effect of olanzapine in the treatment of schizophrenia and its effect on the expression of plasma MiR-137 and MiR-18b in patients.MethodsIn our hospital (2015.1 ~ 2017.4) treatment of 90 cases of patients with schizophrenia were randomly divided into olanzapine group and risperidone group with 45 cases in each group, the two groups were compared after treatment of positive and negative symptoms scale (PANSS) score, plasma MiR-137, serum MiR-18b, glycerol ester (TG), total three the cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and adverse reaction.ResultsBefore treatment, there was no significant difference in PANSS score of two groups (P>0.05); after 4 weeks, 8 weeks of treatment, two groups of patients with PANSS score before treatment were significantly decreased (P<0.05), but there was no significant difference between the two groups (P>0.05); before the treatment, no statistical significance in two groups MiR-137, MiR-18b, TG, TC, HDL-C, LDL-C level difference (P>0.05); after treatment, the two groups of patients MiR-137, MiR-18b levels were significantly increased (P<0.05), olanzapine group of patients with TG, TC and LDL-C were higher than that of risperidone group (P<0.05); after treatment, no significant differences in clinical efficacy olanzapine group and risperidone group (P>0.05); the incidence of adverse reaction of olanzapine group was 26.67% higher than that of risperidone group 8.89% (P<0.05).ConclusionOlanzapine has little difference with risperidone in the treatment of schizophrenia, it can effectively improve plasma MiR-137 and MiR-18b levels, but has a greater impact on blood lipid metabolism and a higher incidence of adverse reactions.
|